Tissue Polypeptide Specific Antigen (TPS)
Specific circulating fragment of human cytokeratin 18, reflecting active epithelial cell mitotic proliferation rather than total tumor mass.
Standard vs. Optimal Reference RangesU/L
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<80.0 U/L
General reference distribution across unselected commercial populations.
<50.0 U/L
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Released during the S and G2/M phases of the cell cycle as dividing epithelial cells assemble and disassemble intermediate filament networks.
Differential Diagnosis
Elevated Levels (TPS High)
- •Rapidly proliferating epithelial malignancies (breast, prostate, colorectal)
- •Acute liver cell regeneration
Low Levels (TPS Low)
- •Indolent, quiescent, or responding tumor state
- •Cell cycle arrest
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for TPS
- Targeted organ system imaging or functional dynamic testing related to cytokeratin 18 cellular proliferation
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Tissue Polypeptide Specific Antigen - The New England Journal of Medicine (2021). PMID: 34090124
- [2]TPS Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Tissue Polypeptide Specific Antigen (TPS) into overall healthspan optimization.